Sigumir

Sigumir is marketed as a "peptide bioregulator" — a low-molecular-weight peptide complex extracted from the cartilage and bone tissue of young animals, out of the Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology. The claimed mechanism is tissue-specific "peptide bioregulation" of chondrocyte gene expression and the aging chondrocyte secretory phenotype. That mechanism is articulated almost entirely by the originating institute; there is no independent mechanistic literature on Sigumir at all.

The human evidence

One indexed human study names Sigumir: a series of 62 elderly patients with temporomandibular joint disease, treated with Sigumir as part of a multi-component "bioregulating therapy" complex, reporting faster pain resolution and improved mouth opening. It is uncontrolled, unblinded, published in the institute-linked journal Advances in Gerontology, and by design cannot isolate Sigumir's contribution from the co-treatments.

A 2023 institute review asserts efficacy of Sigumir in older patients with osteoarthritis — but the primary trials behind that assertion are not independently indexed in PubMed. A claim without a locatable peer-reviewed source is, for this site's purposes, not evidence. There are no RCTs, no registered trials, and no Western-journal publications.

The animal evidence

The same 2023 review claims efficacy in OA animal models; again, the underlying studies are not independently retrievable as indexed primary papers under the product name. Related Khavinson-program work exists on other tissues and on defined short peptides (see the Cartalax entry), but nothing published characterizes Sigumir's composition or tests it in a controlled cartilage model open to independent scrutiny.

The circularity problem

The evidence base here is a closed loop: the institute that sells the concept authors the reviews that cite the institute's own unindexed studies. The vendor-literature problem is acute — most citations offered by sellers are conference abstracts, institute monographs, or Russian-language sources that cannot be verified against PubMed, which is why they do not appear in this site's study database. No composition analysis, batch characterization, or pharmacokinetics have been published, and as an oral animal-tissue peptide extract, intact absorption of active peptides is pharmacologically doubtful and undemonstrated.

Regulatory status and safety

Sigumir is sold as a supplement, typically as "20 mg complex" capsules in 30-day courses; no indexed publication validates any dose. It has no FDA approval or evaluation for any indication, and marketing claims of cartilage regeneration are unsupported by indexed trials. No published safety data exist beyond the absence of reported adverse events in the small TMJ series. Animal-tissue extracts carry theoretical purity and immunogenicity concerns — and unknown risk is not the same as low risk.

What would change the picture

A Sigumir trial registered and published in an indexed, independent journal, or independent chemical characterization of what the capsules actually contain. Neither exists.